ImmunityBio Inc (NASDAQ:IBRX) price closed lower on Tuesday, March 26, dropping -5.88% below its previous close.
A look at the daily price movement shows that the last close reads $5.44. The company’s 5Y monthly beta was ticking 0.00. Taking into account the 52-week price action we note that the stock hit a 52-week high of $6.93 and 52-week low of $1.25. The stock added 22.20% on its value in the past month.
ImmunityBio Inc, which has a market valuation of $3.45 billion, is expected to release its quarterly earnings report Mar 12, 2024 – Mar 16, 2024. Analysts tracking IBRX have forecast the quarterly EPS to shrink by -0.16 per share this quarter, while the same analysts predict the annual EPS to hit -$0.68 for the year 2024 and up to -$0.45 for 2025. In this case, analysts estimate an annual EPS growth of 40.90% for the year and 33.80% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $20k, with the likely lows of $20k and highs of $20k. The average estimate suggests sales growth for the quarter will likely fall by -94.40% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $9.68 million for the company’s annual revenue in 2024. Per this projection, the revenue is forecast to grow 1,456.30% above that which the company brought in 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give IBRX a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
The overview shows that IBRX’s price is at present -1.28% off the SMA20 and 14.19% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.32, with weekly volatility standing at 13.22%. The indicator jumps to 9.85% when calculated based on the past 30 days. ImmunityBio Inc (NASDAQ:IBRX)’s beta value is holding at 1.09, while the average true range (ATR) indicator is currently reading 0.53.
An analysis of the ImmunityBio Inc (NASDAQ:IBRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.01 million. However, this figure increases on the past 10-day timeline to an average of 4.71 million.
Current records show that the company has 670.87M in outstanding shares. The insiders’ percentage holdings are 80.43% of outstanding shares while the percentage share held by institutions stands at 8.49%. The stats also highlight that short interest as of Feb 29, 2024, stood at 51.55 million shares, which puts the short ratio at the time at 11.49. From this we can glean that short interest is 7.69% of company’s current outstanding shares. Notably, we see that shares short in February rose slightly given the previous month’s figure stood at 43.93 million. But the 1.99% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
